(Q38076077)

English

Retigabine for the adjunctive treatment of adults with partial-onset seizures in epilepsy with and without secondary generalization : a NICE single technology appraisal

scientific article published on February 2013

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

0 references

1 reference

Europe PubMed Central

Retigabine for the adjunctive treatment of adults with partial-onset seizures in epilepsy with and without secondary generalization : a NICE single technology appraisal (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

author name string

Dawn Craig

1

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Stephen Rice

2

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Fiona Paton

3

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

David Fox

4

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Nerys Woolacott

5

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

publication date

1 February 2013

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

PharmacoEconomics

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

31

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

101-110

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Single technology appraisal at the UK National Institute for Health and clinical excellence: a source of evidence and analysis for decision making internationally

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0018-1

21 January 2018

Alitretinoin for severe chronic hand eczema: a NICE single technology appraisal

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0018-1

21 January 2018

Cetuximab for recurrent and/or metastatic squamous cell carcinoma of the head and neck: a NICE single technology appraisal

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0018-1

21 January 2018

Febuxostat for the management of hyperuricaemia in patients with gout: a NICE single technology appraisal

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0018-1

21 January 2018

Denosumab for the prevention of osteoporotic fractures in post-menopausal women: a NICE single technology appraisal.

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0018-1

21 January 2018

Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing chemotherapy: a NICE single technology appraisal.

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0018-1

21 January 2018

Dronedarone for the treatment of atrial fibrillation: a NICE single technology appraisal

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0018-1

21 January 2018

Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip or knee surgery: a NICE single technology appraisal

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0018-1

21 January 2018

Golimumab for the treatment of psoriatic arthritis: a NICE single technology appraisal

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0018-1

21 January 2018

Eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a NICE single technology appraisal

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0018-1

21 January 2018

Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years: a NICE single technology appraisal

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0018-1

21 January 2018

Bevacizumab for metastatic colorectal cancer: a NICE single technology appraisal

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0018-1

21 January 2018

Pazopanib for the first-line treatment of patients with advanced and/or metastatic renal cell carcinoma : a NICE single technology appraisal

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0018-1

21 January 2018

National General Practice Study of Epilepsy: newly diagnosed epileptic seizures in a general population

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0018-1

21 January 2018

Zonisamide for add-on treatment of refractory partial epilepsy: a European double-blind trial.

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0018-1

21 January 2018

Management of the patient with medically refractory epilepsy.

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0018-1

21 January 2018

Likelihood of seizure remission in an adult population with refractory epilepsy

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0018-1

21 January 2018

Early identification of refractory epilepsy

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0018-1

21 January 2018

Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0018-1

21 January 2018

Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0018-1

21 January 2018

Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0018-1

21 January 2018

Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0018-1

21 January 2018

Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0018-1

21 January 2018

Adjunctive lacosamide for partial-onset seizures: Efficacy and safety results from a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0018-1

21 January 2018

Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0018-1

21 January 2018

Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0018-1

21 January 2018

Pregabalin add-on treatment in patients with partial seizures: a novel evaluation of flexible-dose and fixed-dose treatment in a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0018-1

21 January 2018

Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0018-1

21 January 2018

Pregabalin add-on therapy using a flexible, optimized dose schedule in refractory partial epilepsies: a double-blind, randomized, placebo-controlled, multicenter trial

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0018-1

21 January 2018

Tiagabine for complex partial seizures: a randomized, add-on, dose-response trial

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0018-1

21 January 2018

Randomized, controlled clinical trial of zonisamide as adjunctive treatment for refractory partial seizures

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0018-1

21 January 2018

Evaluation of health status in epilepsy using the EQ-5D questionnaire: a prospective, observational, 6-month study of adjunctive therapy with anti-epileptic drugs

1 reference

https://api.crossref.org/works/10.1007%2FS40273-012-0018-1

21 January 2018

The new antiepileptic drugs: a systematic review of their efficacy and tolerability

1 reference

https://pubmed.ncbi.nlm.nih.gov/23341194

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trastuzumab for the treatment of HER2-positive metastatic gastric cancer : a NICE single technology appraisal

1 reference

https://pubmed.ncbi.nlm.nih.gov/23341194

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures

1 reference

https://pubmed.ncbi.nlm.nih.gov/23341194

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Results of treatment changes in patients with apparently drug-resistant chronic epilepsy

1 reference

https://pubmed.ncbi.nlm.nih.gov/23341194

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tiagabine therapy for complex partial seizures. A dose-frequency study. The Tiagabine Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/23341194

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bivalirudin for the treatment of ST-segment elevation myocardial infarction: a NICE single technology appraisal

1 reference

https://pubmed.ncbi.nlm.nih.gov/23341194

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Golimumab for the treatment of ankylosing spondylitis: a NICE single technology appraisal

1 reference

https://pubmed.ncbi.nlm.nih.gov/23341194

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trabectedin for the treatment of advanced metastatic soft tissue sarcoma: a NICE single technology appraisal

1 reference

https://pubmed.ncbi.nlm.nih.gov/23341194

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A double-blind, placebo-controlled trial of tiagabine given three-times daily as add-on therapy for refractory partial seizures

1 reference

https://pubmed.ncbi.nlm.nih.gov/23341194

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cabazitaxel for the second-line treatment of metastatic hormone-refractory prostate cancer: a NICE single technology appraisal

1 reference

https://pubmed.ncbi.nlm.nih.gov/23341194

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying antirheumatic drugs: a NICE single technology appraisal.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23341194

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma : a NICE single technology appraisal

1 reference

https://pubmed.ncbi.nlm.nih.gov/23341194

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S40273-012-0018-1

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38076077&oldid=2201240661"